PromarkerD Diagnostic Test Leader Officially Launched
20 March 2018 - 7:00AM
JCN Newswire (English)
PromarkerD, the world leading predictive diagnostic test for DKD,
launched in Dominican Republic this month, with new markets planned
in mainland USA, Mexico, Japan, Australia, China and Europe
PERTH, W. AUSTRALIA, Mar 20, 2018 - (ACN Newswire) - MedTech
pioneer Proteomics International Laboratories Ltd (Proteomics
International; ASX: PIQ) has announced the official product launch
of its world leading predictive diagnostic test for diabetic kidney
disease, "PromarkerD".
The pioneering diagnostic test was launched by Proteomics
International partner Omics Global Solutions (Puerto Rico, USA)
through its distributor in the Dominican Republic, Macrotech
Farmaceutica, the exclusive provider of dialysis services in the
country.
The successful launch represents the achievement of a key milestone
in the stepped approach to commercialise the test in global markets
using a range of technology platforms. Proteomics International is
engaged with potential partners to bring PromarkerD to market in
mainland USA, Mexico, Japan, Australia, China and Europe.
Proteomics International Managing Director, Dr Richard Lipscombe
said, "The world is now recognising the growing burden of diabetes
and the importance of kidney health. We see PromarkerD as
transforming the diagnosis and treatment of diabetic kidney disease
and saving healthcare systems billions of dollars."
The test is being provided using the published mass spectrometry
technology platform, known as a Laboratory Developed Test (LDT),
and the Company expects to conclude its next licensing deal for
this version of PromarkerD with a certified laboratory within
weeks. Following uptake by specialised facilities, Proteomics
International is focused on finalising the development of the in
vitro diagnostic (IVD) immunoassay version of PromarkerD, that can
be used in clinical laboratories around the world.
About Diabetes and Kidney Disease :
The International Diabetes Federation estimates 422 million adults
worldwide now have diabetes, which is the major cause of kidney
disease accounting for approximately 44% of new cases. One in three
adult diabetics will develop chronic kidney disease (CKD). CKD is a
disorder in which patients show progressive loss of kidney (renal)
function usually accompanied by excess protein in the urine
(proteinuria). Ninety percent of kidney function can be lost
without experiencing any symptoms and in Australia 53 people die
every day from the disease.
Many CKD patients progress to a need for dialysis or kidney
transplant, or experience excessive mortality from
cardiovascular-related diseases. The prevalence of CKD is rising
and as such there is urgent need for early diagnosis and treatments
that can benefit CKD patients. Medicare spending in the USA for
patients with chronic kidney disease aged 65 and older exceeded
US$50 billion in 2013, and represented 20% of all Medicare spending
in this age group.
About Omics Global Solutions and Macrotech Farmaceutica :
Omics Global Solutions (OGS) was established to launch innovative
products based on the "omics" sciences (proteomics, genomics, etc.)
to have an impact on the lives of patients, their caregivers, and
medical professionals involved with their treatment. Located in
Puerto Rico (USA) it has partnered with Macrotech Farmaceutica to
serve the population of Latin America.
Macrotech Farmaceutica, established 1995, is a leading health
services company and is the exclusive provider of dialysis
services, instruments and reagents in the Dominican Republic. The
PromarkerD test is branded locally as INNOVATIO ND2.
About Proteomics International Laboratories (PILL) :
Proteomics International is a wholly owned subsidiary of PILL (ASX:
PIQ), a medical technology company at the forefront of predictive
diagnostics and bio-analytical services. The company specialises in
proteomics - the industrial scale study of the structure and
function of proteins.
It received the world's first ISO 17025 laboratory accreditation
for proteomics services, and operates from state-of-the-art
facilities located on the QEII Medical Campus in Perth,
W.Australia. The Company's business model uses its proprietary
technology across three integrated areas of diagnostics, drug
discovery and analytical services.
www.proteomicsinternational.com.
For further information, contact:
Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com
[Investor Relations]
Paul Hart
Canary Capital
T: +61 421 051 474
E: phart@canarycapital.com.au
[Media Contact]
Susan Fitzpatrick-Napier
Director, Digital Mantra Group
T: +61 2 8218 2144
E: team@dmgpr.com
Source: Proteomics International Laboratories Ltd (PILL)
Copyright 2018 ACN Newswire . All rights reserved.
Proteomics International... (ASX:PIQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Proteomics International... (ASX:PIQ)
Historical Stock Chart
From Apr 2023 to Apr 2024